Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Top Cited Papers
- 31 March 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 16 (5), 522-530
- https://doi.org/10.1016/s1470-2045(15)70122-1
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
This publication has 22 references indexed in Scilit:
- Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?Current Opinion in Oncology, 2012
- Prognosis in Patients With Sentinel Node–Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography CriteriaJournal of Clinical Oncology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up GuidelinesJournal of Clinical Oncology, 2010
- Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus MacrometastasesJournal of Clinical Oncology, 2010
- Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysisJNCI Journal of the National Cancer Institute, 2010
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic MelanomaClinical Cancer Research, 2007
- Gene Expression Profiling of Primary Cutaneous Melanoma and Clinical OutcomeJNCI Journal of the National Cancer Institute, 2006
- Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trialsCancer Treatment Reviews, 2003